大流行期间传染病临床试验机构的运营策略:范围综述
该范围综述检索了PubMed和Embase中关于COVID-19、HIV/AIDS、埃博拉、SARS、MERS、H1N1和寨卡七种大流行的文献,最终纳入55篇文章。研究通过主题分析归纳了试验机构在政策、资源、网络、基础设施、技术等方面的运营策略、挑战与经验教训,指出需加强基础设施、人员能力和机构适应性,并解决全球不平等问题。
要点
- 大流行期间临床试验机构采取了系统性运营变革以维持研究。
- 关键挑战包括方案与实践脱节、基础设施碎片化、监管瓶颈和资源不足。
- 需制度化早期站点参与、适应性设计和公平合作以应对未来大流行。
核心结论
- 临床试验机构在大流行期间实施了系统性运营变革以维持研究。
- 关键教训包括需加强基础设施、人员能力和机构适应性,并解决持续的全球不平等。
- 制度化早期站点参与、适应性设计和公平合作对未来大流行中及时且有韧性的临床研究响应至关重要。
研究设计与样本
- 范围综述,聚焦COVID-19、HIV/AIDS、埃博拉、SARS、MERS、H1N1和寨卡七种大流行。
- 检索PubMed和Embase(2024年9月至2025年2月),获得7572条唯一记录,经双人筛选后47篇符合纳入标准,额外通过引文搜索纳入8篇,共55篇。
- 非英语文章使用Google Translate翻译,数据提取并通过迭代熟悉、关键词识别、编码和共识讨论进行主题分析。
主要发现
- 55篇文章中,大多数来自欧洲区域(61%)和美洲(52%),非洲(19%)、西太平洋(8%)、东地中海(5%)和东南亚(5%)也有代表;百分比超过100%是因为多项研究跨多个区域报告。
- 研究设计以描述性为主(60%),随机对照试验(22%)、观察性研究(18%)和队列研究(2%)较少。
- COVID-19占文章多数(58%),其次是HIV/AIDS(20%)、埃博拉(13%)、H1N1(2%)和寨卡(4%);没有合格研究涉及SARS或MERS。
- 运营主题包括政策(73%)、资源(55%)、网络(53%)、基础设施(47%)、技术(45%)、研究设计(31%)和沟通(22%)。
- 报告的挑战包括方案与实践脱节、基础设施碎片化、监管瓶颈和资源不足的站点;实践包括早期站点参与方案开发、简化伦理和合同流程、投资数字和分散式基础设施以及交叉培训员工;差距包括适应性试验设计使用有限和跨国合作不足。
临床怎么用
- 早期让临床试验站点参与方案开发,可提升方案可行性与执行效率。
- 简化伦理审查和合同流程,有助于在大流行期间快速启动试验。
- 投资数字和分散式基础设施,并培训交叉能力人员,可增强试验韧性。
- 采用适应性试验设计并加强跨国合作,以弥补当前差距。
- 关注并解决全球资源不平等,确保各区域站点具备应对能力。
局限性
- 仅检索PubMed和Embase两个数据库,可能遗漏其他数据库文献。
- 非英语文章通过Google Translate翻译,可能存在翻译偏差。
- 纳入研究以描述性为主,随机对照试验较少,证据级别有限。
- 无合格研究涉及SARS或MERS,相关大流行经验覆盖不足。
- 地域分布不均,欧洲和美洲占多数,其他区域代表性有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The aim of this study is to examine documented strategies, challenges, and lessons related to clinical trial site operations during pandemics. METHODS: This review focused on seven major pandemics: COVID-19, HIV/AIDS, Ebola, SARS, MERS, H1N1, and Zika. Searches were conducted using PubMed and Embase between September 2024 and February 2025, yielding 7572 unique records. After dual screening, 47 articles met inclusion criteria, with an additional 8 identified through citation searching, for a total of 55. Non-English articles were translated using Google Translate. Data were extracted and thematically analyzed through iterative familiarization, keyword identification, coding, and consensus discussion. RESULTS: Of the 55 included articles, most originated from the European Region (61%) and the Americas (52%), with additional representation from Africa (19%), the Western Pacific (8%), Eastern Mediterranean (5%), and Southeast Asia (5%). Percentages exceed 100% because several studies reported across multiple regions. Study designs were predominantly descriptive (60%) with fewer randomized controlled trials (22%), observational (18%), and cohort studies (2%). COVID-19 accounted for the majority of articles (58%), followed by HIV/AIDS (20%), Ebola (13%), H1N1 (2%), and Zika (4%); no eligible studies addressed SARS or MERS. Operational themes included policy (73%), resources (55%), networks (53%), infrastructure (47%), technology (45%), study design (31%), and communication (22%). Publications peaked during pandemic years, reflecting intensified research activity. Reported challenges included protocol-practice misalignment, fragmented infrastructure, regulatory bottlenecks, and under-resourced sites. Reported practices included early site engagement in protocol development, streamlined ethics and contracting processes, investment in digital and decentralized infrastructure, and cross-trained staff. Gaps included limited use of adaptive trial designs and insufficient cross-national collaboration. CONCLUSIONS: Clinical trial sites implemented systemic operational changes to sustain research during pandemics. Key lessons include the need to strengthen infrastructure, workforce capacity, and institutional adaptability, and the need to address persistent global inequities. Institutionalizing early site engagement, adaptive designs, and equitable collaboration will be essential to enable timely and resilient clinical research responses in future pandemics.
引用
- Trigg KL, Zhang A, Wu AW, et al. Operational strategies among infectious disease clinical trial sites during pandemics: a scoping review. Trials. 2026. PMID: 41943131. doi:10.1186/s13063-026-09677-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。